Freenome
Company

Freenome

Freenome develops blood-based cancer detection technology using biological measurements, computational analysis and clinical research.

Healthcare & Biotech
  • Founded 2014
  • Headquarters South San Francisco, California, United States
  • CEO Aaron Elliott
Visit Website

Overview

  • Founded
    2014
  • Headquarters
    South San Francisco, California, United States
  • Industry
    Biotechnology
  • CEO
    Aaron Elliott
  • Founders
    Gabriel Otte, Riley Ennis
  • Funding
    Private investment

About Freenome

Freenome is a biotechnology company developing blood-based tests for the early detection of cancer. Its approach combines biological measurements with computational analysis, looking for patterns that may help identify disease through a sample that is easier to obtain than many existing diagnostic procedures.

The company’s research uses a multiomics framework, examining information from more than one type of biological signal. Machine learning is used to interpret those signals and develop test models. Turning that work into a clinical product requires studies that establish how a test performs in the population and setting for which it is intended.

Freenome’s work includes cancer screening, where the distinction between detecting a possible signal and confirming a diagnosis is important. A screening result may need to be followed by additional medical evaluation. Clinical adoption also depends on factors such as testing logistics, regulatory review and how the result fits into established care pathways.

The company combines laboratory science, data analysis and clinical development. Its business objective is to make early detection tools available through healthcare systems and appropriate clinical channels. That requires more than demonstrating an interesting biomarker: a test must produce useful, reproducible information and be supported by evidence relevant to its intended use. Freenome’s long-term commercial prospects therefore depend on the validation and delivery of its diagnostic products as well as the research behind them.

Click to see more